...
首页> 外文期刊>Autoimmunity reviews >Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials
【24h】

Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials

机译:抗SSA / Ro和SSB / La抗体预防母亲后代的先天性新生儿心脏传导阻滞:已发表文献和已注册临床试验的综述

获取原文
获取原文并翻译 | 示例

摘要

Offspring of women with anti-SSA/Ro-SSB/La antibodies are believed to be at risk for congenital heart block (CHB). Whether this risk can be reduced, and what constitutes standard of care treatment is, however, unclear. The objective of this review therefore was to determine whether currently proposed standard of care treatments to avoid CHB in offspring of mothers at risk are evidence-based. To do so, we conducted a review of the literature under appropriate keywords and phrases in Medline/PubMed and Google Scholar for the years 2000-2013. Reference lists were further reviewed, and relevant manuscripts were pulled. We also reviewed www.clinicaltrials.gov for registered studies. In the absence of randomized prospective clinical trials, a meta-analysis was not feasible. We, therefore, reviewed lower evidence level studies individually. Risk of CHB actually appears more closely associated with general autoimmunity than, specifically, with SSA/Ro-SSB/La antibodies. This and other observations raise questions whether CHB is caused by passively transferred maternal autoimmunity, as is currently widely believed. Observational studies suggest the possible effectiveness of intravenous gamma globulin (IV-Ig) and hydroxychloroquine (Plaquenil) in reducing CHB-risk. Evidence for both is, however, inconclusive, and studies are biased in favor of hydroxychloroquine and against IV-Ig. Based on the review of the literature, current evidence of effectiveness for any treatment has to be judged as insufficient. Among the available treatment options, some considerations favor IV-Ig over hydroxychloroquine or, alternatively, suggest treatment with IV-Ig periconceptionally and into early gestation, with hydroxychloroquine added or replacing IV-Ig at approximately 10. weeks gestational age. Benefits for the utilization of steroid drugs are unclear. Since no treatment can be considered as established, prevention of CHB in offspring should be considered experimental, and performed under appropriate study conditions.
机译:具有抗SSA / Ro-SSB / La抗体的女性后代有患先天性心脏传导阻滞(CHB)的风险。但是,目前尚不清楚这种风险是否可以降低以及什么构成护理标准。因此,本次审查的目的是确定目前提议的避免在有风险的母亲的后代中避免CHB的护理标准是基于证据的。为此,我们对2000-2013年间Medline / PubMed和Google学术搜索中适当关键字和短语下的文献进行了回顾。参考文献清单得到进一步审查,相关的手稿也被删除。我们还审查了www.clinicaltrials.gov进行的注册研究。在缺乏随机前瞻性临床试验的情况下,进行荟萃分析是不可行的。因此,我们分别审查了较低证据水平的研究。实际上,与普通的自身免疫相比,CHB的风险似乎与SSA / Ro-SSB / La抗体更紧密相关。正如目前广泛认为的那样,这一观点和其他观察结果引起了人们对CHB是否由被动转移的母体自身免疫引起的质疑。观察性研究表明,静脉内丙种球蛋白(IV-Ig)和羟氯喹(Plaquenil)可能会降低CHB风险。然而,两者的证据尚无定论,并且研究偏向于羟氯喹和IV-Ig。根据对文献的回顾,必须将当前对任何疗法均有效的证据判断为不足。在可用的治疗方案中,某些考虑因素会优先考虑使用IV-Ig而不是羟氯喹,或者建议在孕周大约10周时,在受孕期和妊娠早期用IV-Ig进行治疗,并添加或取代IV-Ig。使用类固醇药物的益处尚不清楚。由于不能认为已建立治疗方案,因此应将后代CHB的预防视为实验性的,并在适当的研究条件下进行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号